The Effects of Facilitated Percutaeous Coronary Intervention in Acute Myocardial Infarction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-01-31

Study Completion Date

2007-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study to investigate whether the administration of high-dose tirofiban before primary PCI could reduce myocardial infarct size, using analysis of contrast-enhanced magnetic resonance imaging.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction

NCT02131220

Myocardial Infarction Percutaneous Coronary Intervention Thrombolytic Therapy

COMPLETED PHASE4

Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients

NCT03114995

Non-ST Elevation Myocardial Infarction

COMPLETED PHASE4

Effect of Upstream High Bolus Dose of Tirofiban in Primary PCI for the Patients With STEMI on Short Term Outcome

NCT04111289

High Bolus Dose of Tirofiban

UNKNOWN PHASE1/PHASE2

Early Initiation of Low Dose Tirofiban for PPCI in STEMI Patients.

NCT03797729

ST Elevation Myocardial Infarction

UNKNOWN PHASE4

Tirofiban Intracoronary Bolus-only Versus Intravenous Bolus Plus Infusion in STEMI Patients

NCT01109134

Acute Myocardial Infarction

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Aspirin, clopidogrel, unfractionated heparin plus tirofiban infusion at high bolus dose

Group Type EXPERIMENTAL

tirofiban

Intervention Type DRUG

tirofiban (25 μg/kg bolus and 0.15 μg/kg/min maintenance infusion for 24 hours)

2

Aspirin, clopidogrel, unfractionated heparin

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tirofiban

tirofiban (25 μg/kg bolus and 0.15 μg/kg/min maintenance infusion for 24 hours)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* presence of chest pain for more than 30 minutes but less than 12 hours after symptom onset
* ST-segment elevation more than 1 mm in two or more contiguous leads or presumably a new-onset left bundle branch blockage

Exclusion Criteria

* hemodynamic instability
* history of MI
* old age \> 80years
* Patients with bleeding diathesis (coagulopathy, thrombocytopenia or platelet dysfunction, Gastrointestinal or genitourinary bleeding within the prior 3 months)

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No